CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2024-08-21 , DOI: 10.1002/alz.14152
Britney N Lizama ₁ , Claire Williams ₁ , Hilary A North ₁ , Kiran Pandey ₂ , Duc Duong ₃ , Valentina Di Caro ₁ , Adam P Mecca ₄ , Kaj Blennow _{5,

6,

7,

8} , Henrik Zetterberg _{7,

8,

9,

10,

11,

12} , Allan I Levey ₁₃ , Michael Grundman _{14,

15} , Christopher H van Dyck ₄ , Anthony O Caggiano ₁ , Nicholas T Seyfried ₃ , Mary E Hamby ₁

Affiliation

Cognition Therapeutics, Pittsburgh, Pennsylvania, USA.
Emtherapro Inc, Systems Biology, Atlanta, Georgia, USA.
Emory University School of Medicine, Biochemistry, Atlanta, Georgia, USA.
Department of Psychiatry, Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.
Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, Anhui, P.R. China.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Göteborg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Göteborg, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Emory University School of Medicine, Neurology, Atlanta, Georgia, USA.
Global R&D Partners, LLC, San Diego, California, USA.
Dept. of Neurosciences, University of California, San Diego, California, USA.

CT1812 is in clinical development for the treatment of Alzheimer's disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate AD from two independent clinical trials.

中文翻译：